Disubstituted amino acids and methods of preparation and use thereof

US9604919B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-9604919-B2
Application numberUS-201314070306-A
CountryUS
Kind codeB2
Filing dateNov 1, 2013
Priority dateNov 1, 2012
Publication dateMar 28, 2017
Grant dateMar 28, 2017

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

Provided are crystalline α, α-disubstituted amino acids and their crystalline salts containing a terminal alkene on one of their side chains, as well as optionally crystalline halogenated and deuterated analogs of the α, α-disubstituted amino acids and their salts; methods of making these, and methods of using these.

First claim

Opening claim text (preview).

What is claimed is: 1. A crystalline salt of a compound of Formula (I): wherein: R 1 is C 1 -C 3 alkyl, C 1 -C 3 deuteroalkyl, or C 1 -C 3 haloalkyl; * is a stereocenter; n is an integer from 3 to 11; R 2 is 9-Fluorenylmethoxycarbonyl (Fmoc); and R 3 is —H; and wherein the salt is a cyclic amine salt. 2. The crystalline salt of claim 1 , wherein R 1 is C 1 -C 3 alkyl. 3. The crystalline salt of claim 1 , wherein R 1 is methyl. 4. The crystalline salt of claim 1 , wherein n is selected from the group consisting of: 3 and 6. 5. The crystalline salt of any one of claims 1 - 3 and 4 , wherein the stereocenter * is (S). 6. The crystalline salt of any one of claims 1 - 3 and 4 , wherein the stereocenter * is (R). 7. The crystalline salt of claim 1 , having a chemical purity ranging from about 90% to 100%. 8. The crystalline salt of claim 1 , having an optical purity ranging from about 90% to 100%. 9. The crystalline salt of claim 1 , having an optical purity ranging from about 95% to 100%. 10. The crystalline salt of claim 1 , having an enantiomeric excess ranging from about 90% to 100%. 11. The crystalline salt of claim 1 , having an enantiomeric excess ranging from about 95% to 100%. 12. The crystalline salt of claim 1 , wherein the compound has a Formula (IIa): 13. The crystalline salt of claim 12 , wherein the crystalline salt has an enantiomeric excess of about 95% to 100%. 14. The crystalline salt of claim 1 , wherein the compound has a Formula (IIb): 15. The crystalline salt of claim 14 , wherein the crystalline salt has an enantiomeric excess of about 95% to 100%. 16. The crystalline salt of claim 1 , wherein the compound has a Formula (Ma): 17. The crystalline salt of claim 16 , wherein the compound or its crystalline salt has an enantiomeric excess of about 95% to 100%. 18. The crystalline salt of claim 1 , wherein the compound has a Formula (IIIb): 19. The crystalline salt of claim 18 , wherein the crystalline salt has an enantiomeric excess of about 95% to 100%. 20. The crystalline salt of claim 1 , wherein n is 3. 21. The crystalline salt of claim 1 , wherein the cyclic amine is selected from a group consisting of cyclopropylamine, cyclobutylamine, cyclopentylamine, cyclohexylamine, cycloheptylamine, and cyclooctylamine. 22. The crystalline salt of claim 1 , wherein the cyclic amine is cyclohexylamine. 23. A method of making a peptide, the method comprising reacting the crystalline salt of claim 1 with an amino acid building block in presence of a coupling agent, thereby forming a peptide bond. 24. The method of claim 23 , wherein the peptide comprises an α-helix. 25. The method of claim 23 , further comprising crosslinking a pair of terminal alkene side chains of at least two amino acids of the peptide. 26. The method of claim 25 , wherein the crosslinking comprises a metal-catalyzed olefin metathesis reaction.

Assignees

Inventors

Classifications

  • C07C271/34Primary

    with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms · CPC title

  • Separation; Purification; Stabilisation; Use of additives · CPC title

  • Optical isomers · CPC title

  • Chemistry & Metallurgy · mapped topic

  • C07C271/22Primary

    to carbon atoms of hydrocarbon radicals substituted by carboxyl groups · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US9604919B2 cover?
Provided are crystalline α, α-disubstituted amino acids and their crystalline salts containing a terminal alkene on one of their side chains, as well as optionally crystalline halogenated and deuterated analogs of the α, α-disubstituted amino acids and their salts; methods of making these, and methods of using these.
Who is the assignee on this patent?
Aileron Therapeutics Inc
What technology area does this patent fall under?
Primary CPC classification C07C271/34. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Mar 28 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 5 related publications on this page (citations in our corpus or others sharing the same primary CPC).